Literature DB >> 26241053

From mice to humans: developments in cancer immunoediting.

Michele W L Teng, Jerome Galon, Wolf-Herman Fridman, Mark J Smyth.   

Abstract

Cancer immunoediting explains the dual role by which the immune system can both suppress and/or promote tumor growth. Although cancer immunoediting was first demonstrated using mouse models of cancer, strong evidence that it occurs in human cancers is now accumulating. In particular, the importance of CD8+ T cells in cancer immunoediting has been shown, and more broadly in those tumors with an adaptive immune resistance phenotype. This Review describes the characteristics of the adaptive immune resistance tumor microenvironment and discusses data obtained in mouse and human settings. The role of other immune cells and factors influencing the effector function of tumor-specific CD8+ T cells is covered. We also discuss the temporal occurrence of cancer immunoediting in metastases and whether it differs from immunoediting in the primary tumor of origin.

Entities:  

Mesh:

Year:  2015        PMID: 26241053      PMCID: PMC4588291          DOI: 10.1172/JCI80004

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  120 in total

1.  Effector memory T cells, early metastasis, and survival in colorectal cancer.

Authors:  Franck Pagès; Anne Berger; Matthieu Camus; Fatima Sanchez-Cabo; Anne Costes; Robert Molidor; Bernhard Mlecnik; Amos Kirilovsky; Malin Nilsson; Diane Damotte; Tchao Meatchi; Patrick Bruneval; Paul-Henri Cugnenc; Zlatko Trajanoski; Wolf-Herman Fridman; Jérôme Galon
Journal:  N Engl J Med       Date:  2005-12-22       Impact factor: 91.245

2.  Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures.

Authors:  Marie-Caroline Dieu-Nosjean; Martine Antoine; Claire Danel; Didier Heudes; Marie Wislez; Virginie Poulot; Nathalie Rabbe; Ludivine Laurans; Eric Tartour; Luc de Chaisemartin; Serge Lebecque; Wolf-Herman Fridman; Jacques Cadranel
Journal:  J Clin Oncol       Date:  2008-09-20       Impact factor: 44.544

3.  Interleukin-17D mediates tumor rejection through recruitment of natural killer cells.

Authors:  Timothy O'Sullivan; Robert Saddawi-Konefka; Emilie Gross; Miller Tran; Stephen P Mayfield; Hiroaki Ikeda; Jack D Bui
Journal:  Cell Rep       Date:  2014-05-01       Impact factor: 9.423

4.  Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy.

Authors:  John Stagg; Sherene Loi; Upulie Divisekera; Shin Foong Ngiow; Helene Duret; Hideo Yagita; Michele W Teng; Mark J Smyth
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-11       Impact factor: 11.205

Review 5.  Oncogene addiction and immunity: clinical implications of tumour infiltrating lymphocytes in breast cancers overexpressing the HER2/neu oncogene.

Authors:  Peter Savas; Franco Caramia; Zhi Ling Teo; Sherene Loi
Journal:  Curr Opin Oncol       Date:  2014-11       Impact factor: 3.645

6.  Cancer: Antitumour immunity gets a boost.

Authors:  Jedd D Wolchok; Timothy A Chan
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

7.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Authors:  Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

8.  Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma.

Authors:  Mohammad Atefi; Earl Avramis; Amanda Lassen; Deborah J L Wong; Lidia Robert; David Foulad; Michael Cerniglia; Bjoern Titz; Thinle Chodon; Thomas G Graeber; Begonya Comin-Anduix; Antoni Ribas
Journal:  Clin Cancer Res       Date:  2014-05-08       Impact factor: 12.531

9.  Adaptive immunity maintains occult cancer in an equilibrium state.

Authors:  Catherine M Koebel; William Vermi; Jeremy B Swann; Nadeen Zerafa; Scott J Rodig; Lloyd J Old; Mark J Smyth; Robert D Schreiber
Journal:  Nature       Date:  2007-11-18       Impact factor: 49.962

10.  A proposed role for neutrophil extracellular traps in cancer immunoediting.

Authors:  Sivan Berger-Achituv; Volker Brinkmann; Ulrike Abu Abed; Lars I Kühn; Jonathan Ben-Ezra; Ronit Elhasid; Arturo Zychlinsky
Journal:  Front Immunol       Date:  2013-03-06       Impact factor: 7.561

View more
  101 in total

1.  Leveraging premalignant biology for immune-based cancer prevention.

Authors:  Avrum Spira; Mary L Disis; John T Schiller; Eduardo Vilar; Timothy R Rebbeck; Rafael Bejar; Trey Ideker; Janine Arts; Matthew B Yurgelun; Jill P Mesirov; Anjana Rao; Judy Garber; Elizabeth M Jaffee; Scott M Lippman
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-16       Impact factor: 11.205

2.  Role of CXC group chemokines in lung cancer development and progression.

Authors:  Artjoms Spaks
Journal:  J Thorac Dis       Date:  2017-04       Impact factor: 2.895

Review 3.  The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer.

Authors:  Jeffrey P Ward; Matthew M Gubin; Robert D Schreiber
Journal:  Adv Immunol       Date:  2016-02-10       Impact factor: 3.543

Review 4.  B lymphocytes and cancer: a love-hate relationship.

Authors:  Grace J Yuen; Ezana Demissie; Shiv Pillai
Journal:  Trends Cancer       Date:  2016-12

Review 5.  Coevolution of Leukemia and Host Immune Cells in Chronic Lymphocytic Leukemia.

Authors:  Noelia Purroy; Catherine J Wu
Journal:  Cold Spring Harb Perspect Med       Date:  2017-04-03       Impact factor: 6.915

6.  PD-1 blockade at the time of tumor escape potentiates the immune-mediated antitumor effects of a melanoma-targeting monoclonal antibody.

Authors:  Laetitia They; Henri-Alexandre Michaud; Ondine Becquart; Virginie Lafont; Bernard Guillot; Florence Boissière-Michot; Marta Jarlier; Caroline Mollevi; Jean-François Eliaou; Nathalie Bonnefoy; Laurent Gros
Journal:  Oncoimmunology       Date:  2017-07-20       Impact factor: 8.110

Review 7.  Signaling from T cell receptors (TCRs) and chimeric antigen receptors (CARs) on T cells.

Authors:  Ling Wu; Qianru Wei; Joanna Brzostek; Nicholas R J Gascoigne
Journal:  Cell Mol Immunol       Date:  2020-05-25       Impact factor: 11.530

Review 8.  Cancer immunotherapy: harnessing the immune system to battle cancer.

Authors:  Yiping Yang
Journal:  J Clin Invest       Date:  2015-09-01       Impact factor: 14.808

Review 9.  Combination cancer immunotherapies tailored to the tumour microenvironment.

Authors:  Mark J Smyth; Shin Foong Ngiow; Antoni Ribas; Michele W L Teng
Journal:  Nat Rev Clin Oncol       Date:  2015-11-24       Impact factor: 66.675

Review 10.  The multifaceted roles of fatty acid synthesis in cancer.

Authors:  Florian Röhrig; Almut Schulze
Journal:  Nat Rev Cancer       Date:  2016-09-23       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.